The FDA Is Pulling Compounded GLP-1 Drugs. Here Is What to Do Before Your Supply Runs Out.
The FDA Is Pulling Compounded GLP-1 Drugs. Here Is What to Do Before Your Supply Runs Out.
4 minute read
The FDA issued warning letters to 30 telehealth companies in March 2026 for making false or misleading claims about compounded GLP-1 products. A month earlier, in February 2026, the agency announced it intends to take formal action against non-FDA-approved GLP-1 drugs, including compounded versions that were permitted during shortage periods.¹
If you are currently on a compounded semaglutide or tirzepatide product obtained through a telehealth platform, the access you have had is likely ending. What replaces it requires navigating the standard insurance process, which takes time and sometimes takes several attempts to get right. Starting that process now, before you are cut off, is the difference between a manageable transition and a gap in treatment.
Why Compounded GLP-1s Were Available
Compounded medications are produced by pharmacies outside the FDA's standard drug approval process. They are permitted under specific circumstances, primarily when a commercially available drug is on the FDA's shortage list and patients cannot access it through normal supply channels.
Semaglutide injection entered the FDA shortage list in 2022, when the explosive demand for Ozempic and Wegovy outpaced Novo Nordisk's manufacturing capacity. The shortage opened a legal window for compounding pharmacies to produce semaglutide-based products, and a significant number of telehealth companies built businesses around prescribing and distributing those compounded versions.
Compounded drugs are not FDA-approved. The FDA does not review their safety, effectiveness, or quality before they go to market. Compounded semaglutide is not the same as branded Ozempic or Wegovy, and generic drug equivalence rules do not apply to it.² The companies that marketed these products in ways that implied equivalence with FDA-approved drugs are the ones receiving warning letters now.
What the FDA Actions Mean in Practice
The shortage designation that permitted compounding is being withdrawn as the branded supply has normalized. With that withdrawal goes the legal basis for most compounded GLP-1 production.
The warning letters sent in March 2026 cited two primary violations: telehealth companies making claims implying their compounded products are the same as FDA-approved versions, and companies marketing drugs under their own branding without making clear the products are compounded.¹ These letters are enforcement signals. They precede additional action.
The practical effect for patients is that telehealth companies will either reformulate their offerings around FDA-approved drugs, adjust their pricing to reflect those drugs' actual costs, or close the GLP-1 piece of their business. Some will do all three. If you have been relying on a compounded supply at the lower price point many telehealth companies offered during the shortage era, the supply pathway you have been using is unlikely to remain available in its current form.
What Comes Next for Coverage
Moving from a compounded product to an FDA-approved GLP-1 medication means returning to the standard formulary and prior authorization process for branded drugs.
The FDA-approved branded GLP-1 medications include Ozempic and Wegovy (semaglutide), Zepbound and Mounjaro (tirzepatide), and, as of early 2026, oral options including Wegovy pill and Foundayo (orforglipron). Your insurer's formulary may include some of these and not others, and prior authorization will be required for most of them.
A prior authorization request for a GLP-1 medication needs to document your medical situation clearly. This includes your weight history, your body mass index, any weight-related conditions such as type 2 diabetes, hypertension, obstructive sleep apnea, or cardiovascular disease, and any prior weight loss treatments you have tried. Insurers frequently deny initial GLP-1 prior authorization requests for obesity on the basis that medical necessity documentation is insufficient. An appeal with complete documentation succeeds more often than the initial request, but taking the time to submit a thorough initial request avoids that cycle entirely.
What to Do Now
Do not wait until your compounded supply is cut off. Processing a prior authorization typically takes one to two weeks for a standard review. If your request is denied and you need to file an appeal, that adds time. Start the process with your prescriber now, so you have a transition plan before any supply gap happens.
Ask your prescriber to submit a prior authorization for an FDA-approved GLP-1. If you do not have a current prescribing relationship with a physician who can submit this on your behalf, establishing one is your first step. The telehealth relationship you had for your compounded prescription may not be the right platform for submitting a standard insurance prior authorization for a branded drug.
Ask specifically about cardiovascular coverage criteria. For patients with established cardiovascular disease, some GLP-1 medications have been approved for cardiovascular risk reduction, which creates an additional coverage pathway beyond the obesity indication. If you have relevant cardiovascular history, make sure your physician documents it in the prior authorization submission.
If you are denied, appeal. Initial GLP-1 denials for obesity are among the most commonly appealed and overturned categories of specialty drug denials. If your denial letter cites a specific clinical criterion that was not met, your prescriber can often address that criterion directly in the appeal documentation.
The transition from compounded to branded GLP-1 coverage is a process with real administrative steps. If you receive a denial during that transition and want to understand what happened and what comes next, Ellen can walk you through it.
Sources: